Mar 1, 1974

Evaluation of commercial antiglobulin sera over a two-year period. Part II. Anti-IgG and anti-IgM levels and undesirable contaminating antibodies

P D IssittS L Wilkinson


Antiglobulin sera, from nine different manufacturers, have been tested over a two-year period for their ability to detect different nonagglutinating, IgG and IgM blood group antibodies and for the presence of undesirable antibodies that cause the agglutination of nonglobulin coated red blood cells. There are not so many differences in anti-IgG levels among the sera as there are differences in anticomplement levels. Over the two-year period, there have been, in general, increases in the amounts of anti-IgM antibodies in the sera tested. Several of the sera, apparently prepared by dilution of raw rabbit serum and not by adsorption, contain antibodies that cause the agglutination of red blood cells not coated with IgG, IgM, or any of the components of complement.

Mentioned in this Paper

Complement Inactivator Proteins
Red blood cells, blood product
Phosphoglycerate Dehydrogenase Activity
Anti-Human Globulin Consumption Test
Observation Method - Agglutination
PHGDH wt Allele
Complement Cytolysis Inhibitor Proteins
Red Blood Cell Count Measurement

Related Feeds

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.